IRIS
LASELVA, ONOFRIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.396
EU - Europa 1.358
AS - Asia 949
SA - Sud America 270
AF - Africa 22
OC - Oceania 3
Continente sconosciuto - Info sul continente non disponibili 2
Totale 4.000
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.319
IE - Irlanda 509
SG - Singapore 456
BR - Brasile 221
IT - Italia 218
HK - Hong Kong 155
RU - Federazione Russa 146
SE - Svezia 132
CN - Cina 130
UA - Ucraina 117
VN - Vietnam 95
DE - Germania 64
CA - Canada 59
FI - Finlandia 52
IN - India 35
GB - Regno Unito 28
AR - Argentina 19
FR - Francia 19
NL - Olanda 13
TR - Turchia 13
MX - Messico 12
BD - Bangladesh 9
EC - Ecuador 9
AT - Austria 8
PL - Polonia 8
BE - Belgio 6
CZ - Repubblica Ceca 6
ES - Italia 6
IQ - Iraq 6
MA - Marocco 6
AE - Emirati Arabi Uniti 5
CL - Cile 5
CO - Colombia 5
MK - Macedonia 5
UZ - Uzbekistan 5
DK - Danimarca 4
ID - Indonesia 4
IR - Iran 4
KE - Kenya 4
PK - Pakistan 4
PY - Paraguay 4
ZA - Sudafrica 4
BG - Bulgaria 3
IL - Israele 3
JP - Giappone 3
TH - Thailandia 3
TN - Tunisia 3
UY - Uruguay 3
AU - Australia 2
AZ - Azerbaigian 2
BS - Bahamas 2
DO - Repubblica Dominicana 2
EE - Estonia 2
ET - Etiopia 2
JO - Giordania 2
KR - Corea 2
KZ - Kazakistan 2
LB - Libano 2
LT - Lituania 2
PE - Perù 2
RO - Romania 2
TW - Taiwan 2
VE - Venezuela 2
AL - Albania 1
AM - Armenia 1
BA - Bosnia-Erzegovina 1
BH - Bahrain 1
CG - Congo 1
EG - Egitto 1
EU - Europa 1
GR - Grecia 1
KG - Kirghizistan 1
LC - Santa Lucia 1
LU - Lussemburgo 1
LV - Lettonia 1
MM - Myanmar 1
NI - Nicaragua 1
OM - Oman 1
PH - Filippine 1
PT - Portogallo 1
RS - Serbia 1
SA - Arabia Saudita 1
SN - Senegal 1
TO - Tonga 1
VA - Santa Sede (Città del Vaticano) 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 4.000
Salva come PNG Salva come JPEG
Città #
Dublin 509
Chandler 241
Singapore 226
Ashburn 165
Hong Kong 146
Nyköping 94
Santa Clara 71
The Dalles 63
Jacksonville 60
Dallas 57
Beijing 46
Princeton 46
Helsinki 42
Moscow 37
Ho Chi Minh City 35
Wilmington 31
Los Angeles 27
New York 24
Pune 23
Hanoi 20
Council Bluffs 19
Milan 16
Des Moines 14
Toronto 14
Bari 13
Redwood City 13
Nuremberg 12
São Paulo 12
Düsseldorf 11
Munich 11
Denver 9
Frankfurt am Main 9
Rio de Janeiro 9
Rome 9
San Mateo 9
Assago 8
Manfredonia 8
Santa Marinella 8
Seattle 8
Cedar Knolls 7
Chicago 7
Haiphong 7
San Jose 7
Torino 7
Andria 6
Belo Horizonte 6
Porto Alegre 6
San Francisco 6
San Severo 6
Brno 5
Brussels 5
Cocoa 5
Da Nang 5
Dubai 5
Espoo 5
Falkenstein 5
Foggia 5
Houghton 5
Palermo 5
Portsmouth 5
Quito 5
Shanghai 5
Tashkent 5
Amsterdam 4
Brooklyn 4
Campinas 4
Can Tho 4
Goiânia 4
Guangzhou 4
Johannesburg 4
Leawood 4
London 4
Nairobi 4
Ottawa 4
San Nicolás de los Garza 4
Skopje 4
Thái Bình 4
Turku 4
Vinhedo 4
Warsaw 4
Ankara 3
Atlanta 3
Aubervilliers 3
Bismarck 3
Biên Hòa 3
Boardman 3
Bắc Ninh 3
Calgary 3
Caserta 3
Catania 3
Contagem 3
Hamilton 3
Kocaeli 3
Kunming 3
Lomas de Zamora 3
Manaus 3
Mogi Guaçu 3
Montevideo 3
Moose Jaw 3
Nanjing 3
Totale 2.438
Salva come PNG Salva come JPEG
Nome #
D1152H MUTATION SHOWS A BICARBONATE BUT NOT A CHLORIDE DEFECT IN PRIMARY NASAL EPITHELIAL CELLS 128
Correctors of mutant CFTR enhance subcortical cAMP/PKA signaling via ezrin phosphorylation and cytoskeleton organization 123
Anti-Inflammatory and Anti-Oxidant Effect of Dimethyl Fumarate in Cystic Fibrosis Bronchial Epithelial Cells 120
AN ADENOVIRAL VECTOR EXPRESSING CFTR CAN BE USED TO BENCHMARK CFTR MODULATOR RESPONSES IN PATIENT-DERIVED NASAL EPITHELIAL CELLS 89
Antisense oligonucleotide splicing modulation as a novel Cystic Fibrosis therapeutic approach for the W1282X nonsense mutation 88
CFTR interactome mapping using the mammalian membrane two-hybrid high-throughput screening system 86
Anticipating New Treatments for Cystic Fibrosis: A Global Survey of Researchers 83
Characterization of anti-proliferative and anti-oxidant effects of nano-sized vesicles from Brassica oleracea L. (Broccoli) 82
Lung Disease Management by Iloprost-Loaded Nanoparticles to Address Hyperinflammation Associated with Cystic Fibrosis 81
Insulin-Like Growth Factor Binding Protein (IGFBP-6) as a Novel Regulator of Inflammatory Response in Cystic Fibrosis Airway Cells 80
Anti-infectives enhance ORKAMBI rescue of F508del-CFTR function in human bronchial epithelial cells infected with clinical strains of P. aeruginosa 80
Anticipating New Treatments for Cystic Fibrosis: A Global Survey of Researchers 79
Comprehensive mapping of Cystic Fibrosis mutations to CFTR protein identifies mutation clusters and molecular docking predicts corrector binding site 79
MODULATION OF CFTR BY ITS PHOSPHORYLATION AND INTERACTION WITH SMALL MOLECULES 79
Human Amniotic Mesenchymal Stem Cells and Fibroblasts Accelerate Wound Repair of Cystic Fibrosis Epithelium 78
Activity of Lumacaftor is not conserved in zebrafish Cftr bearing the major Cystic Fibrosis-causing mutation 78
The preclinical discovery and development of the combination of ivacaftor + tezacaftor used to treat cystic fibrosis 77
A helper-dependent adenoviral vector rescues CFTR to wild type functional levels in CF epithelial cells harbouring class I mutations 77
Allele-specific prevention of nonsense-mediated decay in cystic fibrosis using homology-independent genome editing 75
Modulator Therapy in Cystic Fibrosis Patients with cis Variants in F508del Complex Allele: A Short-Term Observational Case Series 75
MODELING CYSTIC FIBROSIS DISEASE AND THERAPIES IN PATIENT DERIVED TISSUES 73
Identification of binding sites for ivacaftor on the cystic fibrosis transmembrane conductance regulator 73
Correctors of the major Cystic Fibrosis mutant interact through membrane spanning domains 72
ASSESSING THE NEED FOR CORRECTOR COMBINATIONS FOR MISFOLDED CF VARIANTS OTHER THAN F508DEL 71
Editorial: Mechanisms of Novel Drugs and Gene Modifiers in the Treatment of Cystic Fibrosis 70
The era of CFTR modulators: improvements made and remaining challenges 70
Rescue of multiple class II CFTR mutations by elexacaftor+ tezacaftor+ivacaftor mediated in part by the dual activities of Elexacaftor as both corrector and potentiator 70
Cholesterol interaction directly enhances intrinsic activity of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) 69
High-throughput functional analysis of CFTR and other apically localized proteins in iPSC-derived human intestinal organoids 69
Photochemically Activated Notch Signaling Hydrogel Preferentially Differentiates Human Derived Hepatoblasts to Cholangiocytes 68
IGFBP-6 Network in Chronic Inflammatory Airway Diseases and Lung Tumor Progression 67
HUMAN IPSCS AND NASAL CELL MODELS FOR CFTR THERATYPING 66
TOWARDS THE DETERMINATION OF THE BINDING SITE OF IVACAFTOR ON CFTR THROUGH USE OF PHOTOAFFINITY LABELING PROBES 65
TRIMETHYLANGELICIN (TMA) BINDS DIRECTLY TO PURIFIED WILD-TYPE CFTR 65
STUDYING THE DISTINCT SENSITIVITIES OF CFTR MODULATORS USING ZEBRAFISH-CFTR 65
A new platform for high-throughput therapy testing on iPSC-derived lung progenitor cells from cystic fibrosis patients 64
Human Amniotic Mesenchymal Stem Cells and Fibroblasts AccelerateWound Repair of Cystic Fibrosis Epithelium 63
Insulin-Like Growth Factor Binding Protein (IGFBP-6) as a Novel Regulator of Inflammatory Response in Cystic Fibrosis Airway Cells 62
Phenotyping rare cftr mutations reveal functional expression defects restored by trikaftatm 62
A protocol for identifying the binding sites of small molecules on the cystic fibrosis transmembrane conductance regulator (CFTR) protein 61
Trimethylangelicin promotes the functional rescue of F508del CFTR in CF airway cells 60
Small-molecule drugs for cystic fibrosis: Where are we now? 58
Mucopenetration study of solid lipid nanoparticles containing magneto sensitive iron oxide 56
Olive Leaf Extract (OLE) as a Novel Antioxidant That Ameliorates the Inflammatory Response in Cystic Fibrosis 55
Stage-Specific Generation of Human Pluripotent Stem Cell Derived Lung Models to Measure CFTR Function 54
Molecular mechanism of action of Trimethylangelicin derivatives as CFTR modulators 54
Target Identification with Live-Cell Photoaffinity Labeling and Mechanism of Action Elucidation of ARN23765, a Highly Potent CFTR Corrector 53
Emerging preclinical modulators developed for F508del-CFTR have the potential to be effective for ORKAMBI resistant processing mutants 52
Deleterious effect of Pseudomonas aeruginosa on F508del-CFTR rescued by elexacaftor/tezacaftor/ivacaftor is clinical strain-dependent in patient-derived nasal cells 50
The CFTR mutation c.3452G>C (D1152H) confers an anion selectivity defect in primary airway tissue that can be rescued by Ivacaftor 49
Functional rescue of c.3846G>A (W1282X) in patient-derived nasal cultures achieved by inhibition of nonsense mediated decay and protein modulators with complementary mechanisms of action 48
Orkambi mediated rescue of mucociliary clearance in CF primary respiratory cultures is enhanced by arginine uptake, arginase inhibition and promotion of nitric oxide signalling to the CFTR channel 47
Induced pluripotent stem cells for cystic fibrosis 47
IL-17 family members exert an autocrine pro-inflammatory loop in CF respiratory epithelial cells ex vivo 45
The Oncogenic Theory of Preeclampsia: Is Amniotic Mesenchymal Stem Cells-Derived PLAC1 Involved? 45
Deleterious effect ofP. aeruginosaon F508del-CFTR rescued by Elexacaftor/Tezacaftor/Ivacaftor is clinical-strain dependent in patient-derived nasal cells 44
ORKAMBI/amplifier co-therapy rescues a rare CFTR mutation in gene-edited cells and patient tissue 44
The investigational Cystic Fibrosis drug Trimethylangelicin directly modulates CFTR by stabilizing the first membrane-spanning domain 42
One-Step Formation of Protein-Based Tubular Structures for Functional Devices and Tissues 42
Generation of functional ciliated cholangiocytes from human pluripotent stem cells 42
Advances in Preclinical In Vitro Models for the Translation of Precision Medicine for Cystic Fibrosis 41
Preclinical Studies of a Rare CF-Causing Mutation in the Second Nucleotide Binding Domain (c.3700A>G) Show Robust Functional Rescue in Primary Nasal Cultures by Novel CFTR Modulators 41
Elexacaftor/Tezacaftor/Ivacaftor Accelerates Wound Repair in Cystic Fibrosis Airway Epithelium 38
Editorial: Mechanisms of action of small molecules on CFTR mutants and the impact on cystic fibrosis pathogenesis 21
Structure-guided combination of novel CFTR correctors to improve the function of F508del-CFTR in airway epithelial cells 18
Testing organ-specific responses to therapies in tissues differentiated from Cystic Fibrosis patient derived iPSCs 12
Totale 4.240
Salva come PNG Salva come JPEG
Categoria #
all - tutte 30.688
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 30.688
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021255 0 0 0 0 0 5 33 60 68 38 3 48
2021/2022257 15 12 16 3 22 10 16 26 30 32 7 68
2022/20231.222 101 37 28 83 63 121 27 87 600 22 24 29
2023/2024287 31 16 9 8 13 77 16 57 0 7 13 40
2024/20251.047 68 13 22 42 17 221 67 70 246 77 132 72
2025/20261.018 161 156 210 299 118 74 0 0 0 0 0 0
Totale 4.240